Borongan, Daniela B.
HRN: 23-87-35 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/20/2023
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
10/20/2023
11/03/2023
IV
500mg
Q8
Pelvic Inflammatory Disease
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes